SARS-CoV-2 Variant Screening with ELISA Parameter Ranges
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ELISA screening processes for SARS-CoV-2 variants are unpredictable due to virus mutations, leading to inconsistent results and significant resource expenditure without guaranteed success, as different starting materials, cell lines, and incubation times affect outcomes.
Innovation Solution
Specific workable ranges for starting materials, including virus concentrations and incubation periods, are established for various SARS-CoV-2 variants, such as Alpha, Gamma P.1, Beta, Iota, Delta, Omicron BA.1, and Omicron XBB.1.5, using Vero E6 and modified Vero E6-TMPRSS2/ACE2 cells, to standardize the microneutralization assay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ELISA screening processes are used for SARS-CoV-2 variants, then the general screening capability is maintained, but the results become unpredictable and inconsistent due to virus mutations
Solution Approach 1:
The patent applies parameter changes by systematically varying critical assay parameters including starting material concentrations (e.g., serum, virus, antibody titers), incubation times, and cell line types across multiple experimental iterations. This allows optimization of the ELISA and microneutralization assays for each specific SARS-CoV-2 variant, transforming the unreliable traditional approach into a customized, reliable screening method that adapts to viral mutations while maintaining consistent results.
2Reliability
If extensive characterization of starting materials is performed to ensure reliable results, then screening accuracy improves, but the time and resources required increase significantly
Solution Approach 1:
The patent implements preliminary action by establishing standardized protocols for characterizing starting materials before actual screening begins. Critical parameters such as serum quality, antibody titers, and cell line characteristics are pre-validated and documented, creating a reusable knowledge base that eliminates the need to重新 characterize materials for each new screening campaign, thus maintaining high reliability while reducing time investment.
Solution Approach 2:
Through systematic parameter optimization, the patent identifies critical thresholds and workable ranges for various parameters (e.g., minimum serum titers, optimal incubation times). Once these parameters are established for a given variant, they can be reused consistently, reducing the time required for material characterization while maintaining screening accuracy.
3Productivity
If standardized workable ranges for starting materials are established, then screening efficiency improves, but the flexibility to handle novel variants decreases
Solution Approach 1:
The patent creates a universal framework that combines standardized protocols with adaptive elements. The workable ranges established for different variants are organized in a systematic manner that can be applied across multiple variants, allowing efficient screening of known variants while providing a structured approach to adapt to novel variants through controlled parameter adjustments within the established framework.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides systems and processes to screen for SARS-CoV-2. This disclosure teaches specific (and different) workable ranges for starting materials in a screening process for different SARS-CoV-2 variants (e.g., the Washington isolate, Alpha variant, Gamma P.1 variant, Beta variant, Iota variant, Delta variant, Omicron BA.1 variants, etc.). As shown herein, each variant has a different combination of starting materials and incubation periods, which further demonstrates the unpredictability of success that is associated with the disclosed systems and the disclosed processes. To be clear, the general ELISA process is well known by those having skill in the art. However, what is neither well known nor intuitive are the specific parameters associated with different process steps within ELISA. Those specific parameters are the subject of this disclosure.